At VectorBuilder, we push the boundaries of innovation to provide cutting-edge solutions that propel research and development in cell and gene therapy through solving every bottleneck in gene delivery. Our innovations are centered around the three cornerstones of cell and gene therapeutics: Efficacy, Safety, and Manufacturability. De-risk drug development with our time- and cost-effective solutions that boost therapeutic efficacy and efficiency, improve safety profiles, and are primed for clinical and commercial use.
AAV-based gene therapies are often constrained by poor transduction efficiency and off-target delivery, necessitating higher doses that escalate both cost and toxicity. VectorBuilder’s innovative capsid technology provides a powerful solution: engineered capsids with enhanced targeting specificity and maximum gene delivery performance, enabling safer, more effective, and more efficient AAV-based therapeutics.
BrainOptimized for maximum efficiency and streamlined delivery across the blood-brain barrier.
OcularOur ocular capsid boasts excellent pan-retinal penetration and peripheral spread, with superior transduction efficiency in the retinal pigment epithelium (RPE).
MuscularVectorBuilder’s novel capsids significantly enhance targeting and efficiency to skeletal, cardiac, and diaphragm muscles.
MiniVec™VectorBuilder's proprietary MiniVec™ plasmid offers a miniaturized backbone with higher effective yields and translation efficiency. This antibiotic- and supplement-free system streamlines drug development, providing remarkable efficacy, safety, and manufacturability for cell and gene therapies.
MuteFree™ AAVOur novel MuteFree™ AAV backbone has been designed, built, and validated to generate AAV vectors with highly stable ITRs. This results in therapeutic gene products with maximum stability for consistent and high-yield manufacturing.
MegaAAV™Breaking through boundaries of traditional AAV systems, VectorBuilder’s innovative and highly efficacious MegaAAV™ system allows for expression of large genes or complex multi-component systems.
Effective gene delivery is often hindered by fundamental vector limitations, including payload capacity (particularly in AAV vectors), suboptimal gene expression, and poor recombination efficiency. Our innovative vector components address these through shortened promoters that enable more efficient use of limited vector space and optimized coding sequences that drive more robust, consistent transgene expression and enable precise control of gene expression. Leverage our technologies to unlock the full potential of your research for precise, high-performance gene therapies.
Photoreceptor-specificOur shortened photoreceptor promoters are not only significantly smaller, but also boast higher specificity to target cells. All promoters have been validated in mice and/or NHPs. Promoters include high specificity to cone cells (<270 bp), rod cells, and all photoreceptors (200-500 bp).
Beta-globin-specificSupporting development of gene therapies targeting the human beta-globin (HBB) gene with our novel HBB specific promoter (shortened to <1100 bp).
UbiquitousIdeal for use in vector backbones with smaller carrying capacity, our shortened ubiquitous promoter (200-400 bp) allows for design of vectors with larger ORFs and markers without sacrificing viral titer or gene expression levels.
mCherryProviding even more robust expression of mCherry for a wide variety of applications in vitro and in vivo.
Cas9Our codon-optimized HiExpress™ hSpCas9 IVT mRNA ensures consistent, high expression for quick and efficient gene editing.
Cre/LoxAchieve precise control of gene expression using our novel optimized Cre/Lox alongside HiExpress™ Cre for efficient recombination. HiExpress™ Cre is available in two delivery formats:
Explore our full HiExpress™ lineup of codon-optimized RNA products, designed to elevate your discoveries.
服务商工作站 >>
